Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387204 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01387204 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6 participants.
The verdict
NCT01387204, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
GSK1120212 is a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity currently being developed for the treatment of malignant melanoma. This is a Phase I, open-label, non-randomized, single-dose study designed to characterize the absorption, distribution, metabolism, and elimination (ADME) of a single oral dose of MEK inhibitor \[14C\]GSK1120212 as a solution in male subjects with solid tumor malignancies. A sufficient number of subjects will be enrolled to complete approximately four evaluable subjects. Following completion of the study, subjects may elect to continue dosing with GSK1120212 in the rollover study, MEK114375.
Interventions
- DRUG GSK1120212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-02-15 |
| Est. Completion | 2011-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01387204
The ClinicalTrials.gov registry entry for NCT01387204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1120212 is the first listed.
NCT01387204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01387204 about?
NCT01387204 is a clinical study titled "Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212". GSK1120212 is a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity currently being developed for the treatment of malignant melanoma. This is a Phase I, open-label, non-randomized, single-dose study designed to characterize the absorption, distributi...
What is the current status of trial NCT01387204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-02-15. Estimated completion is 2011-07-18.
What interventions are being tested in trial NCT01387204?
The interventions under investigation include: GSK1120212 (DRUG).
Who is sponsoring clinical trial NCT01387204?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.